[go: up one dir, main page]

PE20091106A1 - VACCINE - Google Patents

VACCINE

Info

Publication number
PE20091106A1
PE20091106A1 PE2008002018A PE2008002018A PE20091106A1 PE 20091106 A1 PE20091106 A1 PE 20091106A1 PE 2008002018 A PE2008002018 A PE 2008002018A PE 2008002018 A PE2008002018 A PE 2008002018A PE 20091106 A1 PE20091106 A1 PE 20091106A1
Authority
PE
Peru
Prior art keywords
adenoviric
appe
malaria
vector
protein
Prior art date
Application number
PE2008002018A
Other languages
Spanish (es)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20091106A1 publication Critical patent/PE20091106A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN VECTOR ADENOVIRICO DE SIMIO DEFICIENTE DE REPLICACION C7, QUE CODIFICA UNA PROTEINA DEL CIRCUNSPOROZOITO (PROTEINA CS) DE LA ESPECIE PLASMODIUM FALCIPARUM O UN FRAGMENTO DE LA MISMA QUE COMPRENDE LA SECUENCIA DE SEC ID Nº 1 Y SEC ID Nº 3. SE REFIERE TAMBIEN A UNA COMPOSICION DE VACUNA QUE COMPRENDE: 1) EL VECTOR ADENOVIRICO DE SIMIO DEFICIENTE DE REPLICACION C7; 2) UN ANTIGENO DE LA MALARIA RTS,S; Y 3) UN COADYUVANTE TALES COMO MONOFOSFORIL-LIPIDO A 3-DESACILADO (3D-MPL) Y LA SAPONINA QS21, EN DONDE LA FORMULACION ESTA CONTENIDA EN UNA EMULSION DE ACEITE EN AGUA SIENDO UTIL PARA EL TRATAMIENTO O PROFILAXIS DE LA MALARIAREFERS TO A C7 REPLICATION DEFICIENT APPE ADENOVIRIC VECTOR, WHICH CODES A CIRCUNSPOROZOITE PROTEIN (CS PROTEIN) FROM THE PLASMODIUM FALCIPARUM SPECIES OR A FRAGMENT OF THE SAME THAT INCLUDES SEQUENCE ID NO. SE. IT ALSO REFERS TO A VACCINE COMPOSITION THAT INCLUDES: 1) THE C7 REPLICATION DEFICIENT APPE ADENOVIRIC VECTOR; 2) AN ANTIGEN OF THE MALARIA RTS, S; AND 3) A COADJUVANT SUCH AS 3-DISACILATED MONOPHOSPHORIL-LIPID (3D-MPL) AND SAPONIN QS21, WHERE THE FORMULATION IS CONTAINED IN AN EMULSION OF OIL IN WATER BEING USEFUL FOR THE TREATMENT OR PROPHYLAXIS OF MALARIA

PE2008002018A 2007-12-06 2008-12-04 VACCINE PE20091106A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
PE20091106A1 true PE20091106A1 (en) 2009-08-24

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002018A PE20091106A1 (en) 2007-12-06 2008-12-04 VACCINE

Country Status (20)

Country Link
EP (1) EP2227550A2 (en)
JP (1) JP2011505796A (en)
KR (1) KR20100108544A (en)
CN (1) CN101939438A (en)
AR (1) AR069568A1 (en)
AU (1) AU2008333208A1 (en)
BR (1) BRPI0819889A2 (en)
CA (1) CA2707245A1 (en)
CL (1) CL2008003614A1 (en)
CO (1) CO6300795A2 (en)
CR (1) CR11537A (en)
DO (1) DOP2010000164A (en)
IL (1) IL205953A0 (en)
MA (1) MA32003B1 (en)
MX (1) MX2010006207A (en)
PE (1) PE20091106A1 (en)
TW (1) TW200938633A (en)
UY (1) UY31510A1 (en)
WO (1) WO2009071613A2 (en)
ZA (1) ZA201003851B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
EA027236B1 (en) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (en) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Application of FGL2 protein as malaria infection marker

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
JP5404990B2 (en) * 2002-10-23 2014-02-05 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム How to vaccinate against malaria
SG156535A1 (en) * 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
ATE449105T1 (en) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio CHIMPANZEE ADENOVIRUS VACCINE CARRIAGE
EP1802336B1 (en) * 2004-10-14 2011-09-07 Crucell Holland B.V. Malaria prime/boost vaccines
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
KR20090092752A (en) * 2006-07-18 2009-09-01 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccines for malaria
EP2998316B1 (en) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
CN101939438A (en) 2011-01-05
KR20100108544A (en) 2010-10-07
CL2008003614A1 (en) 2010-01-15
MA32003B1 (en) 2011-01-03
MX2010006207A (en) 2010-10-04
JP2011505796A (en) 2011-03-03
ZA201003851B (en) 2012-11-28
UY31510A1 (en) 2009-08-03
DOP2010000164A (en) 2010-07-31
WO2009071613A2 (en) 2009-06-11
CR11537A (en) 2010-08-18
EP2227550A2 (en) 2010-09-15
AR069568A1 (en) 2010-02-03
CA2707245A1 (en) 2009-06-11
AU2008333208A1 (en) 2009-06-11
TW200938633A (en) 2009-09-16
WO2009071613A3 (en) 2009-08-13
IL205953A0 (en) 2010-11-30
CO6300795A2 (en) 2011-07-21
BRPI0819889A2 (en) 2015-06-16

Similar Documents

Publication Publication Date Title
EA201792562A1 (en) GLUCAGON AND COAGONISTS GLP-1
MX2021011949A (en) Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy.
AR050353A1 (en) HER2 ANTIBODY COMPOSITION
MX2022012931A (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE.
PE20091352A1 (en) COMPOSITION INCLUDING ANTIBODY THAT IS FIXED TO DOMAIN II OF HER2, AND ITS ACID VARIANTS
ECSP10010697A (en) DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD
NI201100025A (en) METHODS OF ADMINISTRATION OF TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS.
CO2016000671A1 (en) Constructions of variants of sirp-alfa and their uses
MX2017003121A (en) Antibody formulations.
CL2008002361A1 (en) Use of an antigen derived from plasmodium falciparum circumesporozoite (cs) protein that is expressed in the preerythrocytic stage of malaria infection to treat babies against malaria.
EA201890638A1 (en) DEVIATING ACIDS, CONTAINING WATER-RESISTANT REDUCTION ACTION, AND WAYS OF MANUFACTURE AND APPLICATION
AR102547A1 (en) VACCINES AGAINST DISEASE OF HANDS, FEET AND MOUTH AND MANUFACTURING METHODS AND THEIR USE
PE20091106A1 (en) VACCINE
BR112017010832A2 (en) amino acid compositions for treating disease symptoms
MX2021000516A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease.
AR099960A1 (en) PROCEDURES AND PHARMACEUTICAL COMPOSITION TO INDUCE AN IMMUNE RESPONSE
EA201001478A1 (en) VACCINE
MX2019002248A (en) MODIFIED H-FACTOR BINDING PROTEIN.
PH12018501646A1 (en) Compositions and methods for treating infections
MX389042B (en) Using a yeast protein extract to stabilise beer cloudiness
AR073967A1 (en) PEPTIDO-EPITOPE RAB6KIFL / KIF20A AND VACCINES CONTAINING THE SAME
MX391376B (en) EGGSHELL MEMBRANE COMPOSITIONS FOR USE IN THE TREATMENT OF NUCLEAR FACTOR KAPPA LIGHT CHAIN OF ACTIVATED B CELLS (NF-KB) IN A HOST ORGANISM.
BRPI0508807A (en) hair treatment composition, use of a hair treatment composition and method
EA201200538A1 (en) ARABINOGALAKTAN TO IMPROVE ACQUIRED IMMUNE RESPONSE
CO2019007671A2 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease

Legal Events

Date Code Title Description
FC Refusal